BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23641951)

  • 1. Autotaxin inhibitors: a patent review.
    Barbayianni E; Magrioti V; Moutevelis-Minakakis P; Kokotos G
    Expert Opin Ther Pat; 2013 Sep; 23(9):1123-32. PubMed ID: 23641951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autotaxin inhibitors: a patent review (2012-2016).
    Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
    Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An updated patent review of autotaxin inhibitors (2017-present).
    Tan Z; Lei H; Guo M; Chen Y; Zhai X
    Expert Opin Ther Pat; 2021 May; 31(5):421-434. PubMed ID: 33342311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer.
    Barbayianni E; Kaffe E; Aidinis V; Kokotos G
    Prog Lipid Res; 2015 Apr; 58():76-96. PubMed ID: 25704398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
    Stein AJ; Bain G; Prodanovich P; Santini AM; Darlington J; Stelzer NM; Sidhu RS; Schaub J; Goulet L; Lonergan D; Calderon I; Evans JF; Hutchinson JH
    Mol Pharmacol; 2015 Dec; 88(6):982-92. PubMed ID: 26371182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autotaxin and LPA receptor signaling in cancer.
    Houben AJ; Moolenaar WH
    Cancer Metastasis Rev; 2011 Dec; 30(3-4):557-65. PubMed ID: 22002750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Function and biological activities of the autotaxin-LPA axis].
    Li ZW; Zhao YR; Zhao C; Fu R; Li ZY
    Sheng Li Xue Bao; 2011 Dec; 63(6):601-10. PubMed ID: 22193457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
    Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
    Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of 2,4-dihydropyrano[2,3-c]pyrazole derivatives as autotaxin inhibitors.
    Pantsar T; Singha P; Nevalainen TJ; Koshevoy I; Leppänen J; Poso A; Niskanen JMA; Pasonen-Seppänen S; Savinainen JR; Laitinen T; Laitinen JT
    Eur J Pharm Sci; 2017 Sep; 107():97-111. PubMed ID: 28687529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode.
    Miller LM; Keune WJ; Castagna D; Young LC; Duffy EL; Potjewyd F; Salgado-Polo F; Engel García P; Semaan D; Pritchard JM; Perrakis A; Macdonald SJ; Jamieson C; Watson AJ
    J Med Chem; 2017 Jan; 60(2):722-748. PubMed ID: 27982588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.
    Gotoh M; Fujiwara Y; Yue J; Liu J; Lee S; Fells J; Uchiyama A; Murakami-Murofushi K; Kennel S; Wall J; Patil R; Gupte R; Balazs L; Miller DD; Tigyi GJ
    Biochem Soc Trans; 2012 Feb; 40(1):31-6. PubMed ID: 22260662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
    Nikolaou A; Ninou I; Kokotou MG; Kaffe E; Afantitis A; Aidinis V; Kokotos G
    J Med Chem; 2018 Apr; 61(8):3697-3711. PubMed ID: 29620892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and optimization of boronic acid based inhibitors of autotaxin.
    Albers HM; van Meeteren LA; Egan DA; van Tilburg EW; Moolenaar WH; Ovaa H
    J Med Chem; 2010 Jul; 53(13):4958-67. PubMed ID: 20536182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface.
    Fells JI; Lee SC; Fujiwara Y; Norman DD; Lim KG; Tsukahara R; Liu J; Patil R; Miller DD; Kirby RJ; Nelson S; Seibel W; Papoian R; Parrill AL; Baker DL; Bittman R; Tigyi G
    Mol Pharmacol; 2013 Sep; 84(3):415-24. PubMed ID: 23793291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and therapeutic potential of autotaxin small molecule inhibitors: From bench to advanced clinical trials.
    Matralis AN; Afantitis A; Aidinis V
    Med Res Rev; 2019 May; 39(3):976-1013. PubMed ID: 30462853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase 10A inhibitors: a 2009 - 2012 patent update.
    Kehler J
    Expert Opin Ther Pat; 2013 Jan; 23(1):31-45. PubMed ID: 23210904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological roles of lysophosphatidic acid signaling through its production by autotaxin.
    Okudaira S; Yukiura H; Aoki J
    Biochimie; 2010 Jun; 92(6):698-706. PubMed ID: 20417246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin.
    Jiang G; Madan D; Prestwich GD
    Bioorg Med Chem Lett; 2011 Sep; 21(17):5098-101. PubMed ID: 21489790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autotaxin inhibition: development and application of computational tools to identify site-selective lead compounds.
    Norman DD; Ibezim A; Scott WE; White S; Parrill AL; Baker DL
    Bioorg Med Chem; 2013 Sep; 21(17):5548-60. PubMed ID: 23816044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.
    Ragle LE; Palanisamy DJ; Joe MJ; Stein RS; Norman DD; Tigyi G; Baker DL; Parrill AL
    Bioorg Med Chem; 2016 Oct; 24(19):4660-4674. PubMed ID: 27544588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.